Pyxis Oncology reprices executive stock options to $2.21 per share

Pyxis Oncology, Inc.

Board approved reducing exercise prices of outstanding pre-IPO options from $5.34-$8.71 to $2.21, the closing price on March 24, 2023.
CEO Lara Sullivan had 1,052,286 options repriced; CFO/COO Pamela Connealy 332,569; CMO Jay Feingold 174,774.
Repricing applies only to options granted under the 2019 Plan to current employees; all other terms unchanged.
Board cites improved retention and motivation without additional equity dilution or cash compensation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.